{"id":44058,"date":"2022-05-18T14:01:18","date_gmt":"2022-05-18T12:01:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/"},"modified":"2022-05-18T14:01:18","modified_gmt":"2022-05-18T12:01:18","slug":"anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/","title":{"rendered":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation"},"content":{"rendered":"
\n

CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma<\/a>, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites in China. Anji plans to report topline data from this study in the second half of 2022.\n<\/p>\n

<\/a><\/p>\n

\n\u201cAchieving full enrollment during a pandemic while ensuring alignment with regulatory expectations of a randomized Phase 2 is a significant endorsement of the Anji development team and our mission to develop programs concurrently in the two largest pharmaceutical markets in the world,\u201d said Greg Dombal, Anji\u2019s Global Head of Development. \u201cWe believe the rapid enrollment in the study underscores the unmet medical need in functional constipation in the U.S. and China.\u201d\n<\/p>\n

\n\u201cCurrent available treatments for functional constipation have very low response rates and often bring undesired side effects,\u201d said May Li, Anji\u2019s Head of Clinical Operations. \u201cThe successful recruitment of this trial is due to our experience working closely with leading hospitals in China and our hub-and-spoke operations based in the U.S. and China.\u201d\n<\/p>\n

\nThe Phase 2 study is a randomized, double-blind, placebo-controlled proof of concept study to assess the efficacy, safety and tolerability of pradigastat in patients with functional constipation. The trial has enrolled over 180 patients, who received one tablet a day of pradigastat 20mg or 40mg, or a placebo. The primary endpoint is the change from baseline in the number of weekly spontaneous bowel movement (SBM) at week 4. The key secondary endpoint is the change from baseline in the number of weekly complete spontaneous bowel movement (CSBM) at week 4. More information about this trial may be accessed at www.clinicaltrials.gov<\/a> (identifier: NCT04620161).\n<\/p>\n

\nPradigastat is an inhibitor of diacylglycerol acyltransferase 1 (DGAT1), which plays a key role in the re-assembly of meal triglycerides and acts as a sensor of dietary fat intake. The inhibition of DGAT1 by pradigastat changes the intestinal milieu by raising the level of fatty acids in the gut lumen. This may lead to increased colon motility and water secretion, two necessary attributes for effective constipation therapy. Pradigastat has the potential to markedly improve treatment of functional constipation and irritable bowel syndrome-associated constipation (IBS-C), two prevalent diseases with few effective treatments.\n<\/p>\n

\nAbout Anji Pharma<\/b>\n<\/p>\n

\nAnji Pharma is a clinical-stage company dedicated to bringing life-changing therapies to patients across the globe. Anji\u2019s asset-centric business model allows for speed and flexibility in building value, leveraging a clinical and regulatory core that operates with \u201chub-and-spoke” efficiency. Anji\u2019s clinical pipeline includes gut-targeted metformin (ANJ900 in Phase 3) intended for glucose management in patients with type 2 diabetes and advanced chronic kidney disease, as well as pradigastat (ANJ908 in Phase 2) for treatment of functional constipation. For more info, visit www.anjipharma.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCorporate:
\n
Michael Serrano-Wu, Ph.D.
\n
info@anjipharma.com<\/a>\n<\/p>\n

\nMedia:
\n
Emily Wong
\n
MacDougall Advisors
\n
AnjiPharmaceuticals@macdougall.bio<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44058","6":"format-standard","7":"category-industry"},"yoast_head":"\nAnji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-18T12:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation\",\"datePublished\":\"2022-05-18T12:01:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/\"},\"wordCount\":504,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005100\\\/en\\\/1458516\\\/21\\\/Anji_Pharma_-_new_logo_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/\",\"name\":\"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005100\\\/en\\\/1458516\\\/21\\\/Anji_Pharma_-_new_logo_%281%29.jpg\",\"datePublished\":\"2022-05-18T12:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005100\\\/en\\\/1458516\\\/21\\\/Anji_Pharma_-_new_logo_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220518005100\\\/en\\\/1458516\\\/21\\\/Anji_Pharma_-_new_logo_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/","og_locale":"en_US","og_type":"article","og_title":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend","og_description":"CAMBRIDGE, Mass. & SHANGHAI–(BUSINESS WIRE)–Anji Pharma, an emerging global medicines company, today announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. The trial is being conducted in five clinical sites in the U.S. and 20 clinical sites ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-18T12:01:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation","datePublished":"2022-05-18T12:01:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/"},"wordCount":504,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/","url":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/","name":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg","datePublished":"2022-05-18T12:01:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220518005100\/en\/1458516\/21\/Anji_Pharma_-_new_logo_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/anji-pharma-completes-patient-enrollment-in-phase-2-study-of-pradigastat-in-functional-constipation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44058"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44058\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}